source
- Jazz Pharmaceuticals to acquire Actio Biosciences in deal worth over $1.3 billionJazz Pharmaceuticals announced an agreement to purchase Actio Biosciences, a San Diego biotech focused on genetic epilepsies. The transaction could total just over $1.3 billion, with $820 million…
- FDA approves Takeda’s orexin-2 drug Orzeyful for narcolepsy type 1The U.S. Food and Drug Administration has approved Takeda Pharmaceutical's new sleep medication, Orzeyful, marking the first product in the emerging orexin‑2 drug class. Orzeyful works by amplifyi…